Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 4,612 shares at $301.20 ($1.4M) on 2021-11-02, disclosed to the SEC on 2021-11-04.
Open-market sale of $1.4M RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $299.02 | 64 | $19K | 1.4% |
| 2 | $301.20 | 251 | $76K | 5.4% |
| 3 | $301.20 | 251 | $76K | 5.4% |
| 4 | $301.97 | 446 | $135K | 9.6% |
| 5 | $301.97 | 446 | $135K | 9.6% |
| 6 | $303.48 | 532 |
| $161K |
| 11.5% |
| 7 | $303.48 | 532 | $161K | 11.5% |
| 8 | $304.23 | 124 | $38K | 2.7% |
| 9 | $305.91 | 700 | $214K | 15.3% |
| 10 | $305.91 | 700 | $214K | 15.3% |
| 11 | $306.49 | 283 | $87K | 6.2% |
| 12 | $306.49 | 283 | $87K | 6.2% |
| Total | $304.01 avg | 4,612 | $1.4M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |